关键词: 达格列净, 冠状动脉粥样硬化性心脏病, 射血分数保留的心力衰竭

Abstract: Objective  To observe the improvement effect of dapagliflozin on cardiac function in patients with heart failure with preserved ejection fraction (HFpEF) complicated with coronary heart disease. Methods  Patients with coronary heart disease and HFpEF who were hospitalized in the Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University from January 2021 to September 2022 were selected as the research objects. Among them, 69 patients who took dapagliflozin were selected as the dapagliflozin group, and 81 patients who did not take dapagliflozin were selected as the control group. Patients in both groups were treated with standard secondary prevention of coronary heart disease. If there were no contraindications, both groups were given standardized treatment for heart failure. The basic patients’ information were collected by the hospital information system, as well as outpatient follow-up data for 12 months of hospitalization and discharge, including blood glucose, blood lipids, N-terminal pro B-type natriuretic peptide (NT-proBNP) and other laboratory indicators, left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), left ventricular end-systolic dimension (LVESD), left ventricular posterior wall thickness (LVPWT), stroke volume (SV), left ventricular diastolic function E/e'avg et al. And record the cardiac death, acute left heart failure, re-hospitalization for heart failure, re-hospitalization for angina, and adverse drug reactions during hospitalization. Results  The degree of blood lipid and blood glucose control and the improvement of NT-proBNP, LVEF and E/e 'avg in the dapagliflozin group were better than those in control group, the differences were statistically significant (P<0.05). During the follow-up period, the incidence of acute left heart failure and rehospitalization due to heart failure in the dapagliflozin group was significantly lower than those in control group, the differences were statistically significant (P<0.05). Conclusions Dapagliflozin can improve cardiac diastolic function, reduce NT-proBNP levels, improve quality of life, and readmission rate for heart failure in patients with coronary heart disease complicated with HFpEF. Simultaneously, it has good security.

Key words: dapagliflozin, coronary heart disease, heart failure with preserved ejection fraction